Stockholders Approve New Equity Incentive Plan, Authorizing 1.85 Million Additional Shares
FBRX has more than doubled off its 52-week low of $7.78.
Summary
Forte Biosciences stockholders approved an amended equity incentive plan, authorizing an additional 1.85 million shares for future equity compensation, which could lead to significant dilution.
Key Events · Corporate Governance and Compliance · FBRX
-
Equity Incentive Plan Approved
Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, authorizing a total of 5,190,000 shares for issuance, which includes 1,850,000 newly requested shares.
-
Potential Dilution
The newly authorized 1.85 million shares for the incentive plan represent approximately 9.03% of the company's 20,478,817 outstanding shares, creating significant potential dilution if fully utilized.
-
Routine Annual Meeting Approvals
Stockholders also elected Class III directors, ratified KPMG LLP as the independent registered public accounting firm for 2026, and approved executive compensation on an advisory basis.
Analysis · FBRX · Life Sciences
Forte Biosciences stockholders approved an amended equity incentive plan, authorizing an additional 1.85 million shares for future grants. This approval, following a proposal in April, creates significant potential dilution for existing shareholders if all authorized shares are issued, representing approximately 9.03% of current outstanding shares. While essential for attracting and retaining talent in a biotech firm, it adds to the potential supply of shares in the market.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBRX was trading at $18.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $372.2M. The 52-week trading range was $7.78 to $35.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.